Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > News
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(198)
•••
Comment by Pragmatiston Dec 27, 2020 6:37pm
247 Views
Post# 32185968

RE:News

RE:News
Doccole wrote: Are we expecting any news this week? Or after the new year will stuff start rolling in?

I imagine there is no motivation to get the stock price up when Ceo Dan and the good doc is negotiating a deal with Antibe Holdings (IP).  Correct me if I'm wrong?!


 
The CEO stated during Biopub that he will be submitting the IND shortly after Christmas.  I guess it depends on one's definition of "shortly".  If nothing else, this will get OTEN into the FDA system such that more meanigful discussions can begin.
 
Since Legault/Wallace are the majority SHs of both ATE and AHI, there clearly is a conflict of interest.  I think we will see the Board negotiating on behalf of ATE. The Board has a fiduciary responsibility to SHs, and most board members have substantial holdings (more then half a million post-split for the Chair). They clearly have a vested interest in doing what is right for all SHs, including themselves
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities